The U.S. Food and Drug Administration (FDA) has agreed to review an application seeking the approval of Ofev (nintedanib) for children ages 6 to 17 with fibrosing interstitial lung diseases (ILDs). If approved, Ofev would become the first and only therapy available to treat children with fibrosing ILDs, according…
People with Sjögren’s syndrome-associated interstitial lung disease (ILD) who develop pulmonary fibrosis (PF) have poorer survival than those without PF, a study in Taiwan finds. Researchers found that continuously low albumin levels — a sign of inflammation — could act as a risk factor for developing PF. A smaller…
A three-protein signature can be used to differentiate between idiopathic pulmonary fibrosis (IPF) and other lung disorders and may be a noninvasive biomarker of the rare disease, according to a new study. While the scientists stressed that further research will be needed to validate the…
People with shorter telomeres, or chromosome “caps,” may be at a greater risk of developing idiopathic pulmonary fibrosis (IPF), a study reported. This work “also provided some interesting genetic evidence to prove that obesity and exposure to tobacco smoking as a fetus might also contribute to the development of…
Bridge Biotherapeutics has joined the Prognostic Lung Fibrosis Consortium, known as PROLIFIC — a global nonprofit working to speed the development of personalized treatment strategies for pulmonary fibrosis (PF), The long-term goal of PROLIFIC is to develop tests to detect biomarkers of distinct stages of the rare…
Treatment with a molecule designed to activate the SHP-1 protein led to prolonged survival and alleviation of disease-associated lung changes in a mouse model of idiopathic pulmonary fibrosis (IPF), a study found. SHP-1 activation appeared to exert its protective effects by inhibiting the survival and pro-fibrotic activity of a…
Ofev (nintedanib) more than halved the rate of lung function decline in patients who developed interstitial lung disease (ILD) associated with rheumatoid arthritis (RA), an inflammatory disease. That’s according to data from INBUILD (NCT02999178), a Phase 3 trial of more than 650 adults with progressive fibrosing ILDs in…
A Phase 3 trial of pamrevlumab, an experimental therapy from FibroGen to treat idiopathic pulmonary fibrosis (IPF), failed to meet its primary goal of slowing lung function decline. General safety and tolerability were seen in treated patients in ZEPHYRUS-1 (NCT03955146), which tested 48 weeks of pamrevlumab’s use…
Insilico Medicine made its entry into Phase 2 clinical testing with INS018_055, a small molecule it discovered and designed using artificial intelligence (AI), as a potential treatment for idiopathic pulmonary fibrosis (IPF). Patients have now received the first dose of oral INS018_055 in a randomized placebo-controlled Phase 2…
A new, potentially disease-specific imaging agent may one day allow doctors to identify pulmonary fibrosis (PF) in earlier stages, when the start of treatment can be more effective, according to a study in a mouse model of the disease. Called 64Cu-GPVI-Fc, the agent — coupled with positron emission tomography…
Get regular updates to your inbox.
